Share Email Print
cover

Proceedings Paper

Interstitial photodynamic therapy of canine prostate with meso-tetra-(m-hydroxyphenyl) chlorin and 5-aminolevulinic acid: a preliminary study
Author(s): Shi-Chung Chang; Giovanni A. Buonaccorsi; Alexander J. MacRobert; Stephen G. Bown
Format Member Price Non-Member Price
PDF $14.40 $18.00

Paper Abstract

Photodynamic therapy (PDT) is proved to have potential for managing various malignancies. We investigated tissue biodistribution and photodynamic effects on a canine model in vivo using second generation photosensitizers, meso-tetra(m-hydroxyphenyl)chlorin (mTHPC) and 5-aminolaevulinic acid (ALA) to evaluate the feasibility and possible future application of PDT on the prostate. Using fluorescence microscopy, the optimal sensitization time of the prostate was between 24 - 72 hours with mTHPC and, 3 hours with ALA. After optimum time of sensitization, prostates of mature beagle were treated with laser at various sites by placing fiber interstitially under the guidance of transrectal ultrasound. The light dose for each treatment site was 100 J (100 mW for 1,000 seconds at the wavelength of 650 and 630 nm, respectively). With mTHPC, single laser fiber was able to induce organ confined PDT lesion as large as 20 by 18 by 18 mm in size. However, the PDT lesion with ALA was negligible 3 days after treatment. Physical distress manifested as urinary retention, poor appetite and body weigh loss, was more prominent with increasing number of treatment sites as a result of extensive prostatic swelling and urethral damages. However, these problems usually alleviated spontaneously 7 to 10 days after PDT. The characteristic histological changes were hemorrhagic necrosis and glandular destruction with preservation of interlobular collagen fibers. Urethral damage seen at the early stage healed by regeneration of urothelium in 4 weeks. We conclude that interstitial PDT with mTHPC is technically possible to produce extensive glandular necrosis in the normal prostate which heals safely and does not change the prostatic architecture. ALA, although it seems promising for bladder tumors, is much less effective than mTHPC on the prostate. With mTHPC, it might have the potential for treating prostate cancers localized in the periphery of the gland.

Paper Details

Date Published: 31 January 1996
PDF: 8 pages
Proc. SPIE 2625, Photochemotherapy: Photodynamic Therapy and Other Modalities, (31 January 1996); doi: 10.1117/12.231001
Show Author Affiliations
Shi-Chung Chang, Univ. College London Medical School and Tzu-Chi General Hospital (United Kingdom)
Giovanni A. Buonaccorsi, Univ. College London Medical School (United Kingdom)
Alexander J. MacRobert, Univ. College London Medical School (United Kingdom)
Stephen G. Bown, Univ. College London Medical School (United Kingdom)


Published in SPIE Proceedings Vol. 2625:
Photochemotherapy: Photodynamic Therapy and Other Modalities
Benjamin Ehrenberg; Giulio Jori; Johan Moan, Editor(s)

© SPIE. Terms of Use
Back to Top